Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| RET ~10-20% RET fusions in papillary | 60-70% | RET mutation in medullary thyroid cancer | Wikipedia |
| BRAF Near-universal in some PTC variants | 40-60% | Papillary V600E | cBioPortal (TCGA) |
| NTRK | 2-3% | Fusion | Wikipedia |
| TSH receptor (TSHR) | host% | Host target: TSH receptor on thyroid cells, used to drive radioiodine uptake. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
5 cell lines, 1 mouse models and 3 repositories are listed for this cancer. See them →